Sun Pharmaceuticals Limited on March 4 announced that it is set to acquire 60% shareholding in Vivaldis Health & Foods for Rs 143.30 crore from its existing shareholders. The company is engaged in the business of trading, distributing, manufacturing and marketing of drugs, food supplements and over the counter products in the companion animal segment of animal healthcare industry.
The revenue for the financial year 2021-22 was Rs 29.92 crore. The revenues of Vivaldis Health have grown at CAGR of 47% during FY 19-20 to FY 21-22 period.
“INR 143.30 crores subject to customary closing adjustments for 60% shareholding,' the company said in its filing.
Sun Pharmaceutical Industries is India's top pharmaceutical company and the world's fourth largest specialty generic pharmaceutical company.
The company reported 5.2% rise in consolidated net profit to Rs 2,166 crore in Q3 FY23 as compared with the corresponding quarter last fiscal. Total sales increased by 13% to Rs 11,100.14 crore in the third quarter from Rs 9,814.17 crore in the same period previous year.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.